E
ANIP icon

Ergoteles’s ANI Pharmaceuticals ANIP Stock Holding History

Ergoteles’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,905
Closed -$372K – 81
2023
Q2 		$372K Buy
+6,905
New +$306K 0.02% 717
2022
Q4 		– Sell
-11,484
Closed -$369K – 1427
2022
Q3 		$369K Buy
+11,484
New +$393K 0.01% 882

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ergoteles's ANIP Position: Q3 2023 in Review

Ergoteles sold out of ANI Pharmaceuticals (ANIP) in Q3 2023, closing a stake of 6,905 shares — an estimated $372K sold.

Ergoteles first reported a position in ANIP in Q3 2022 and held it in 2 quarters. The position peaked at $372K in Q2 2023. 186 funds tracked by Wall St. Rank hold ANIP as of Q3 2023.

  • Ergoteles reported no remaining ANI Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 6,905 ANI Pharmaceuticals shares in Q3 2023, an estimated $372K.
  • Ergoteles first reported a position in ANI Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Ergoteles's ANI Pharmaceuticals position peaked at $372K in Q2 2023.
  • 186 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.